M
Marc LaForce
Researcher at Serum Institute of India (India)
Publications - 7
Citations - 141
Marc LaForce is an academic researcher from Serum Institute of India (India). The author has contributed to research in topics: MenAfriVac & Meningococcal vaccine. The author has an hindex of 5, co-authored 7 publications receiving 130 citations.
Papers
More filters
Journal ArticleDOI
Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine.
Paul A. Kristiansen,Fabien Diomandé,Stanley C. Wei,Rasmata Ouédraogo,Lassana Sangaré,Idrissa Sanou,Denis Kandolo,Pascal Kaboré,Thomas A. Clark,Abdoul-Salam Ouédraogo,Ki Ba Absatou,Charles D. Ouédraogo,Musa Hassan-King,Jennifer Dolan Thomas,Cynthia Hatcher,Mamoudou Harouna Djingarey,Nancy E. Messonnier,Marie-Pierre Préziosi,Marc LaForce,Dominique A. Caugant,Dominique A. Caugant +20 more
TL;DR: The baseline carriage rate and serogroup distribution before vaccine introduction in the 1- to 29-year old population in Burkina Faso, the group chosen for the first introduction of the vaccine, forms a solid basis for evaluating the impact of MenAfriVac introduction on serogroups A carriage.
Journal ArticleDOI
Phenotypic and genotypic characterization of meningococcal carriage and disease isolates in Burkina Faso after mass vaccination with a serogroup a conjugate vaccine
Paul A. Kristiansen,Absatou Ky Ba,Idrissa Sanou,Abdoul-Salam Ouédraogo,Rasmata Ouédraogo,Lassana Sangaré,Fabien Diomandé,Denis Kandolo,Jennifer Dolan Thomas,Thomas A. Clark,Marc LaForce,Dominique A. Caugant,Dominique A. Caugant +12 more
TL;DR: Successive clonal waves of ST-181 and ST-11 may explain the changing epidemiology in Burkina Faso after the virtual disappearance of NmA disease and carriage.
Journal ArticleDOI
Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2–29 Years
Aldiouma Diallo,Samba O. Sow,Olubukola T. Idoko,Siddhivinayak Hirve,Helen Findlow,Marie-Pierre Preziosi,Cheryl M. Elie,Prasad S. Kulkarni,Varsha Parulekar,Bou Diarra,Fadima Cheick Haidara,Fatoumata Diallo,Milagritos D. Tapia,Adebayo Akinsola,Richard A. Adegbola,Ashish Bavdekar,Sanjay Juvekar,Julie Chaumont,Lionel Martellet,Elisa Marchetti,Marc LaForce,Brian D. Plikaytis,Godwin Enwere,Yuxiao Tang,Ray Borrow,George M. Carlone,Simonetta Viviani +26 more
TL;DR: Four years after vaccination with a single dose of PsA-TT vaccine in Africa, most subjects are considered protected from MenA disease.
Journal ArticleDOI
The Global Meningitis Genome Partnership
Elizabeth Rodgers,Stephen D. Bentley,Ray Borrow,Holly B. Bratcher,Sylvain Brisse,Angela B. Brueggemann,Dominique A. Caugant,Jamie Findlow,Le Anne M. Fox,Linda Glennie,Lee H. Harrison,Odile B. Harrison,Robert S. Heyderman,Melissa J. Jansen van Rensburg,Keith A. Jolley,Brenda Kwambana-Adams,Shamez N Ladhani,Marc LaForce,Michael Levin,Jay Lucidarme,Neil MacAlasdair,Jenny M. MacLennan,Martin C. J. Maiden,Laura Maynard-Smith,Alessandro Muzzi,Philipp Oster,Charlene M.C. Rodrigues,Olivier Ronveaux,Laura Serino,Vinny Smith,Arie van der Ende,Julio A. Vázquez,Xin Wang,Saber Yezli,James M. Stuart +34 more
TL;DR: The WHO-led collaboration, Defeating Meningitis by 2030 Global Roadmap, has called for the establishment of a Global Meningococcal Genome Partnership that links resources for improved worldwide co-ordination of strain identification and tracking.
Journal ArticleDOI
Laboratory quality control in a multicentre meningococcal carriage study in Burkina Faso.
Paul A. Kristiansen,Abdoul-Salam Ouédraogo,Idrissa Sanou,Absatou Ky Ba,Charles D. Ouédraogo,Lassana Sangaré,Rasmata Ouédraogo,Denis Kandolo,Fabien Diomandé,Pascal Kaboré,Musa Hassan-King,Jennifer Dolan Thomas,Cynthia Hatcher,Ida K. G. Andreasson,Thomas A. Clark,Marie-Pierre Préziosi,Marc LaForce,Dominique A. Caugant,Dominique A. Caugant +18 more
TL;DR: The QC system was a critical element: it identified logistical and operational problems in real time and ensured accuracy of the final data, which was probably slightly underestimated and the calculated true prevalence was 4.48%.